Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 20 de 47
Filter
5.
Int J Trichology ; 15(2): 74-76, 2023.
Article in English | MEDLINE | ID: mdl-37701553

ABSTRACT

Acquired hypertrichosis can occur in local inflammation. Erythema nodosum (EN) is a hypersensitivity reaction to various underlying antigenic stimuli including Mycobacterium tuberculosis, which causes inflammation in the septa of subcutaneous fat. There were several case reports that describe the association of localized hypertrichosis (LH) with traumatic panniculitis and lupus panniculitis. To our knowledge, this is the first reported case of acquired LH associated with EN. Thus, EN can be added to the list of causes of localized hypertrichosis.

6.
J Eur Acad Dermatol Venereol ; 37(12): 2543-2549, 2023 Dec.
Article in English | MEDLINE | ID: mdl-37528459

ABSTRACT

BACKGROUND: Pigmented contact dermatitis (PCD), a rare variant of non-eczematous contact dermatitis, is clinically characterized by sudden-onset brown or grey pigmentation on the face and neck. It is hypothesized to be caused by repeated contact with low levels of allergens. OBJECTIVES: This study evaluated the risk of using hair dyes in patients with PCD in Korea. METHODS: A total of 1033 PCD patients and 1366 controls from 31 university hospitals were retrospectively recruited. We collected and analysed the data from the patient group, diagnosed through typical clinical findings of PCD and the control group, which comprised age/sex-matched patients who visited the participating hospitals with pre-existing skin diseases other than current allergic disease or PCD. RESULTS: Melasma and photosensitivity were significantly more common in the control group, and a history of contact dermatitis was more common in the PCD group. There were significantly more Fitzpatrick skin type V participants in the PCD group than in the control group. There was no significant difference in sunscreen use between the groups. Using dermatologic medical history, Fitzpatrick skin type and sunscreen use as covariates, we showed that hair dye use carried a higher PCD risk (odds ratio [OR] before adjustment: 2.06, confidence interval [CI]: 1.60-2.65; OR after adjustment: 2.74, CI: 1.88-4.00). Moreover, henna users had a higher risk of PCD (OR before adjustment: 5.51, CI: 4.07-7.47; OR after adjustment: 7.02, CI: 4.59-10.74), indicating a significant increase in the risk of PCD with henna dye use. Contact dermatitis history was more prevalent in henna users than in those using other hair dyes in the PCD group (17.23% vs. 11.55%). CONCLUSION: Hair dye use is a risk factor for PCD. The risk significantly increased when henna hair dye was used by those with a history of contact dermatitis.


Subject(s)
Dermatitis, Allergic Contact , Hair Dyes , Humans , Hair Dyes/adverse effects , Retrospective Studies , Dermatitis, Allergic Contact/diagnosis , Dermatitis, Allergic Contact/epidemiology , Dermatitis, Allergic Contact/etiology , Sunscreening Agents , Republic of Korea/epidemiology
8.
Medicina (Kaunas) ; 58(7)2022 Jul 14.
Article in English | MEDLINE | ID: mdl-35888655

ABSTRACT

Melasma is a common pigmentary disorder with a complex pathogenesis, of which the treatment is challenging. Conventional treatment often leads to inconsistent results with unexpected pigmentary side effects and high recurrence rates. Recently, the low-fluence Q-switched Nd:YAG laser (LFQSNY) has been widely used for treating melasma, especially in Asia. We reviewed literatures on the LFQSNY treatment of melasma published between 2009 and May 2022 to evaluate the efficacy and adverse events, including its combination therapy. A systematic PubMed search was conducted and a total of 42 articles were included in this study. It was hard to summarize the heterogenous studies, but LFQSNY appeared to be a generally effective and safe treatment for melasma considering the results of previous conventional therapies. However, mottled hypopigmentation has been occasionally reported to develop and persist as an adverse event of LFQSNY, which may be associated with the high accumulated laser energy. When used aggressively, even LFQSNY can induce hyperpigmentation via unwanted inflammation, especially in darker skin. Although few studies have reported considerable recurrence rates three months after treatment, unfortunately, there is a lack of the long-term follow-up results of LFQSNY in melasma. To enhance the effectiveness and reduce the adverse events, LFQSNY has been used in combination with other treatment modalities in melasma, including topical bleaching agents, oral tranexamic acid, chemical peeling, or diverse energy-based devices, which generally reduced side effects with or without significant superior efficacy compared to LFQSNY alone.


Subject(s)
Hyperpigmentation , Lasers, Solid-State , Low-Level Light Therapy , Melanosis , Combined Modality Therapy , Humans , Lasers, Solid-State/therapeutic use , Melanosis/complications , Melanosis/radiotherapy , Treatment Outcome
9.
J Dermatol ; 49(1): 173-178, 2022 Jan.
Article in English | MEDLINE | ID: mdl-34713476

ABSTRACT

Despite the expanding clinical application of hydroxychloroquine in dermatology, the overall data on hydroxychloroquine use among dermatologists are limited. With retrospective review of the medical records of the 790 patients who were prescribed hydroxychloroquine, we classified the diagnoses into 12 disease categories, the lupus erythematosus group being the largest. The lupus erythematosus group had the longest prescription duration (median, 6.2 months), whereas the photodermatitis group had a significantly shorter prescription duration (median, 0.5 months). The overall good response rate was 77.1%. The photodermatitis group had the best response (88.7%), followed by the lupus panniculitis (85.1%) and lichen planus (84.4%). In conclusion, hydroxychloroquine has proven utility for various inflammatory skin diseases, including but not limited to cutaneous lupus erythematosus.


Subject(s)
Dermatology , Lupus Erythematosus, Cutaneous , Lupus Erythematosus, Systemic , Humans , Hydroxychloroquine/therapeutic use , Lupus Erythematosus, Cutaneous/diagnosis , Lupus Erythematosus, Cutaneous/drug therapy , Republic of Korea , Retrospective Studies
10.
Pediatr Dermatol ; 38(1): 290-291, 2021 Jan.
Article in English | MEDLINE | ID: mdl-33006145

ABSTRACT

Erythema induratum of Bazin (EIB) is a form of tuberculid resulting from hypersensitivity to tuberculosis antigen. EIB occurs most commonly in middle-aged women and is not typically seen in children. Here, we present a rare case of EIB, presenting as a chronic nodular panniculitis, in a 10-year-old Korean boy.


Subject(s)
Erythema Induratum , Hypersensitivity , Panniculitis , Tuberculosis, Cutaneous , Antitubercular Agents/therapeutic use , Child , Erythema Induratum/diagnosis , Erythema Induratum/drug therapy , Female , Humans , Male , Middle Aged , Panniculitis/drug therapy , Tuberculosis, Cutaneous/drug therapy
11.
Pediatr Dermatol ; 36(5): 750-752, 2019 Sep.
Article in English | MEDLINE | ID: mdl-31282037

ABSTRACT

Cryotherapy using liquid nitrogen is an effective and commonly used treatment for palmoplantar warts. However, pain can be a limiting factor in the effective use of cryotherapy. In this study, we found that a single application of anesthetic cream following cryotherapy treatment of warts reduced posttreatment pain and led to improved tolerability of the procedure.


Subject(s)
Anesthetics, Local/therapeutic use , Cryotherapy/adverse effects , Lidocaine, Prilocaine Drug Combination/therapeutic use , Pain/etiology , Pain/prevention & control , Warts/therapy , Adolescent , Child , Female , Humans , Male , Ointments , Treatment Outcome , Young Adult
13.
J Dermatol ; 45(12): 1411-1417, 2018 Dec.
Article in English | MEDLINE | ID: mdl-30222206

ABSTRACT

An association between alopecia areata (AA) and other autoimmune diseases has been reported. We investigated the associations between AA and overt autoimmune thyroid diseases. A nationwide, population-based, cross-sectional study was performed using the Korea National Health Insurance claims database. We defined patients with AA as those whose records showed at least four physician contacts in which AA, alopecia totalis (AT) or alopecia universalis (AU) was the principal diagnosis. We also established an age- and sex-matched control group without AA. In a subgroup analysis, patients with AT or AU were classified into the severe AA group, and the remainder were classified into the mild to moderate AA group. Patients with AA were at an increased risk of Graves' disease (odds ratio [OR], 1.415; 95% confidence interval [CI], 1.317-1.520) and Hashimoto thyroiditis (OR, 1.157; 95% CI, 1.081-1.237), and the associations were stronger in the severe AA group (Graves' disease: OR, 1.714; 95% CI, 1.387-2.118; Hashimoto thyroiditis: OR, 1.398; 95% CI, 1.137-1.719). In conclusion, AA was significantly associated with overt autoimmune thyroid diseases. Furthermore, the risk was much higher in the severe AA group.


Subject(s)
Alopecia Areata/epidemiology , Graves Disease/epidemiology , Hashimoto Disease/epidemiology , Adolescent , Adult , Aged , Aged, 80 and over , Alopecia Areata/diagnosis , Alopecia Areata/immunology , Case-Control Studies , Child , Cross-Sectional Studies , Female , Graves Disease/immunology , Hashimoto Disease/immunology , Humans , Incidence , Male , Middle Aged , Republic of Korea/epidemiology , Risk Factors , Severity of Illness Index , Young Adult
17.
J Am Acad Dermatol ; 76(5): 871-878, 2017 May.
Article in English | MEDLINE | ID: mdl-28238453

ABSTRACT

BACKGROUND: Associations between vitiligo and thyroid diseases have been reported repeatedly. OBJECTIVE: We investigated the associations between vitiligo and overt autoimmune thyroid diseases and thyroid cancer using the Korean National Health Insurance claims database. METHODS: We defined patients with vitiligo as those whose records showed ≥4 physician contacts between 2009 and 2013 in which vitiligo was the principal diagnosis. We also established an age- and sex-matched control group without vitiligo (2 per 1 vitiligo patient). The outcomes of interest were concurrent Graves disease and Hashimoto thyroiditis (the patients were taking relevant thyroid medications) and thyroid cancer. RESULTS: The study enrolled 73,336 vitiligo patients and 146,672 controls. Patients with vitiligo were at increased risks of Graves disease (odds ratio [OR] 2.610 [95% confidence interval {CI} 2.319-02.938]), Hashimoto thyroiditis (OR 1.609 [95% CI 1.437-1.802]), and thyroid cancer (OR 1.127 [95% CI 1.022-1.242]), compared with the controls. The associations were consistently stronger in males and younger patients. LIMITATIONS: Individual clinical information was not available, and the homogeneous population may limit the generalizability of the results. CONCLUSION: Vitiligo was significantly associated with overt autoimmune thyroid diseases and overt thyroid cancer.


Subject(s)
Autoimmune Diseases/epidemiology , Graves Disease/epidemiology , Hashimoto Disease/epidemiology , Thyroid Neoplasms/epidemiology , Vitiligo/epidemiology , Adult , Age Factors , Aged , Aged, 80 and over , Case-Control Studies , Female , Humans , Male , Middle Aged , Republic of Korea/epidemiology , Risk Factors , Sex Factors , Young Adult
18.
J Am Acad Dermatol ; 76(3): e87-e88, 2017 Mar.
Article in English | MEDLINE | ID: mdl-28212772
SELECTION OF CITATIONS
SEARCH DETAIL